Nephrotoxicity is the major limitation for the clinical use of cisplatin as an antitumor. Nanocurcumin, unlike curcumin, is readily dispersed in aqueous media. The purpose of this preliminary study was to investigate the potential of nanocurcumin against cisplatin-induced nephrotoxicity in rats. This study conducted for 9 days treatment, five groups of male Sprague-Dawley rats were examined: normal, cisplatin (CDDP) 7 mg/kgBW, CDDP+curcumin (CMN) 100 mg/kg BW/day, CDDP+nanocurcumin (NC) 50 mg/kg BW/day, and CDDP+NC 100 mg/kg BW/day. After 72 h following injection cisplatin, specimens were collected. Plasma blood urea nitrogen (BUN), plasma creatinine, urinary ureum levels, urinary creatinine levels, MDA levels in kidney, and GSH levels in kidney were investigated. Rats were weighed before and after study. Data were analyzed using one-way analysis of variance (ANOVA). This study resulted a single dose injection of cisplatin caused a significant increase in plasma BUN, plasma creatinine, and MDA levels by 6 fold, 2.4 fold, and 1.4 fold respectively as compared to normal group. Pre-treatment with CMN and NC were reduced plasma BUN levels, plasma creatinine levels, MDA levels in kidney and increased GSH level in kidney compared with CDPP-induced nephrotoxicity rats without treatment. At the end of treatment, the difference of body weight between normal group and CDDP group was statistically significant. CDPP is able to induce nephrotoxicity in rats that mimicked acute kidney injury in human. CMN and NC tend to reduce the CDPP-induced nephrotoxiciy.